What is the most appropriate inpatient management for a patient with atrial fibrillation, complete heart block status post ventricular cardioverter‑defibrillator (VCD) implantation, hypertension, hyperlipidemia, elevated B‑type natriuretic peptide (BNP) (~989 pg/mL), currently on atorvastatin, a multivitamin, and metoprolol, presenting with nursing‑related syncope?

Inpatient Management for Syncope in a Patient with Complete Heart Block, Atrial Fibrillation, and Elevated BNP

The most critical priority is to immediately discontinue or significantly reduce metoprolol, as the combination of beta-blocker therapy with complete heart block is contraindicated and likely precipitated the syncope 1.

Immediate Actions

1. Discontinue or Hold Metoprolol

This patient with complete heart block status post device implantation (likely pacemaker/ICD, though "VCD" appears to be a typo) presenting with syncope while on metoprolol represents a drug-induced exacerbation of conduction disease. Recent evidence demonstrates that the digoxin-beta-blocker combination can precipitate complete AV block in elderly patients with atrial fibrillation, and discontinuation leads to resolution within 72 hours 1. Even without digoxin, metoprolol in the setting of complete heart block poses significant risk for symptomatic bradycardia and syncope.

2. Evaluate Device Function

• Interrogate the pacemaker/ICD immediately to assess:
  • Battery status
  • Lead integrity
  • Pacing thresholds
  • Percentage of ventricular pacing
  • Any stored arrhythmic events

The syncope may represent device malfunction, inappropriate programming, or pacemaker-mediated tachycardia 2.

3. Assess for Structural Heart Disease and Arrhythmia

The elevated BNP of 989 pg/mL suggests heart failure or significant cardiac dysfunction 3, 4. Syncope in patients with underlying heart disease can be a precursor to sudden death and requires thorough evaluation 2.

Obtain:

• 12-lead ECG (assess for ischemia, QT prolongation, device pacing patterns)
• Continuous telemetry monitoring
• Echocardiogram to evaluate:
  • Left ventricular ejection fraction (LVEF)
  • Valvular disease
  • Wall motion abnormalities
  • Pulmonary pressures

The BNP/LVEF ratio is independently associated with atrial fibrillation severity and demonstrates good discriminative performance for cardiac dysfunction 4. Patients with LVEF <40%, heart failure, and elevated BNP have significantly increased in-hospital mortality risk 5.

Risk Stratification

High-risk features present in this patient:

• Complete heart block with device
• Syncope (6-12 fold increased risk of fatal/near-fatal events) 6
• Elevated BNP suggesting heart failure
• Atrial fibrillation
• On beta-blocker with conduction disease

Multivariate analysis shows that heart failure (adjusted OR 2.91), chronic kidney disease (adjusted OR 3.67), and LVEF <40% (adjusted OR 2.74) are independently associated with in-hospital mortality in AF patients 5.

Management Algorithm

Rate Control Strategy (After Metoprolol Discontinuation)

Given complete heart block with device, the patient is already pacemaker-dependent for ventricular rate. The focus shifts to:

1. If LVEF ≤40%: Consider digoxin as sole rate-control agent (Class I) 7. However, use cautiously given the drug interaction risk with beta-blockers that precipitated this presentation 1.

2. If LVEF >40%: Options include digoxin, diltiazem, or verapamil (Class I) 7. Avoid reintroducing beta-blockers given the complete heart block and recent syncope.

3. Target lenient rate control: Resting heart rate <110 bpm, with stricter control only if symptoms persist (Class IIa) 7.

Anticoagulation Management

This patient requires oral anticoagulation given atrial fibrillation with multiple risk factors (hypertension, likely age ≥65) 8.

• Verify current anticoagulation status (not mentioned in current medications)
• If not anticoagulated: Initiate direct oral anticoagulant (DOAC) or warfarin (INR 2.0-3.0) (Class I) 8
• Risk factors present: Hypertension, likely heart failure (elevated BNP), making anticoagulation Class I indication 8

Heart Failure Optimization

The elevated BNP (989 pg/mL) indicates decompensated heart failure or significant cardiac dysfunction 3.

Obtain:

• Chest X-ray for pulmonary congestion
• Renal function and electrolytes
• Consider BNP/LVEF ratio for prognostication 4

If heart failure confirmed:

• Optimize diuretic therapy (already on furosemide—may need adjustment)
• Consider ACE inhibitor/ARB if not already on one
• Evaluate for cardiac resynchronization therapy (CRT) if LVEF <35% and appropriate indications 9

Syncope Workup Completion

Beyond cardiac evaluation 2:

• Orthostatic vital signs (rule out orthostatic hypotension from medications)
• Metabolic panel (electrolytes, renal function)
• Complete blood count (rule out anemia)
• Thyroid function (hyperthyroidism can worsen AF)

Disposition and Monitoring

Admit to telemetry unit with:

• Continuous cardiac monitoring
• Serial troponins if ischemia suspected
• Daily weights and strict intake/output if heart failure present
• Device clinic consultation for interrogation and reprogramming if needed

Common Pitfall: Continuing beta-blocker therapy in a patient with complete heart block and syncope. The combination is contraindicated and potentially life-threatening 1. Even with a functioning pacemaker, beta-blockers can cause symptomatic bradycardia if the device is not appropriately programmed or malfunctioning.

Discharge Planning:

• Revised medication regimen without beta-blocker
• Alternative rate-control agent if needed (digoxin, calcium channel blocker)
• Confirmed anticoagulation
• Device clinic follow-up within 1-2 weeks
• Cardiology follow-up within 2-4 weeks